UCB Acquires Ra Pharma, Adds Zilucoplan to Its MG Pipeline
UCB has completed its acquisition of Ra Pharmaceuticals, priced at about $2.3 billion, meaning that zilucoplan —…
Articles by Joana Carvalho, PhD
Scientists Create 3-D Model to Study Neuromuscular Disorders, Including Myasthenia Gravis
Scientists have created — in a lab dish — a three-dimensional model system made of human neurons and muscle cells…
Difficult-to-treat MG Affects Working Hours and Employment Status, Study Finds
People with refractory myasthenia gravis — those whose symptoms persist after treatment — are more likely to…
First Patient Dosed in Phase 3 Trial of Zilucoplan, Ra Pharma Announces
Ra Pharmaceuticals announced the first patient enrolled in RAISE, the company’s Phase 3 clinical trial assessing the effectiveness…
Long-Term Use of Gabapentin May Trigger MG Exacerbations, Case Report Says
Physicians should keep in mind that severe exacerbations in patients with myasthenia gravis (MG) might be triggered by the…
FDA Grants Orphan Drug Status to Ra Pharma’s Zilucoplan as Potential MG Treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zilucoplan, Ra Pharmaceuticals‘ lead candidate…
MG Metabolic Profile May be Used as Diagnostic, Prognostic Biomarker, Study Says
Scientists discovered that patients with myasthenia gravis have a unique metabolic profile that can be used to diagnose the…
Juvenile MG Should be Considered When Diagnosing Children with Ocular Abnormalities, Case Report Says
Despite being relatively rare in toddlers, juvenile myasthenia gravis should be considered in the differential diagnosis of children showing…
In China, Patients with Rare Diseases Struggle for Affordable Therapies, Study Says
Despite the support from basic health insurance, those in China living with rare diseases, such as myasthenia gravis (MG),…
High PD-L1 Production in Muscle Cells of MG Patients May Play Role in Autoimmunity, Study Says
Muscle cells of myasthenia gravis patients produce large amounts of the programmed cell death ligand 1 (PD-L1) — a…